Market Overview

Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

Share:

POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical
company focused on the development of innovative treatments for
metabolic disorders, including type 2 diabetes and non-alcoholic
steatohepatitis (NASH), announced today that it will be featured as a
presenting company at the H.C. Wainwright 20th Annual Global
Investment Conference.

The H.C. Wainwright 20th Annual Global Investment Conference
is being held on September 4-6th at The St. Regis Hotel
in New York City. The Company will present a corporate overview on
Thursday, September 6th from 10:00-10:25 AM ET in Louis XVI A
room on the 2nd floor and will be available to participate in one-on-one
meetings with investors. The presentation at the H.C. Wainwright 20th
Annual Global Investment Conference will be webcast live. To
access the webcast, please visit the following link http://wsw.com/webcast/rrshq28/poxel.pa/.
The webcast replay will remain available for 90 days following the live
presentation.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline
of drug candidates focused on the treatment of metabolic disorders,
including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We
have successfully completed the Phase 2 clinical program for our
first-in-class lead product, Imeglimin, which targets mitochondrial
dysfunction, in the U.S., Europe and Japan. Together, with our partner
Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of
IMeglimin for Efficacy and Safety (TIMES)
program for the treatment of type 2 diabetes in Japan. Our
partner Roivant Sciences is responsible for Imeglimin's
development and commercialization in countries outside of Poxel's
partnership with Sumitomo Dainippon Pharma, including the U.S. and
Europe. PXL770, a first in class direct adenosine
monophosphate-activated protein kinase (AMPK) activator, is advancing
into a Phase 2a proof-of-concept program for the treatment of NASH.
PXL770 could also have the potential to treat additional metabolic
diseases. DRX-065 (deuterium-stabilized R-pioglitazone), a mitochondrial
pyruvate carrier (MPC), is in Phase 1 and being developed for the
treatment of NASH. Poxel also has additional earlier-stage programs,
including deuterated drug candidates for metabolic, specialty and rare
diseases. We intend to generate further growth through strategic
partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

View Comments and Join the Discussion!